Pay in 4 interest-free payments of $6.47 Learn more
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
46 In Table 2, we have summarized the main differences in clinical characteristics between patients treated with GLP-1RAs in RWS and those enrolled in Phase III trials testing the efficacy of GLP-1RAs on glycemic and extra-glycemic effects (excluding CVOTs)
Liraglutide, a oncedaily human GLP1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD1 SU)
The relationship between dose and effect was close to linear across the studied range
Short-term #pharmacotherapy without a long-term plan #risks disappointment, lost benefit, and misaligned expectationsfor patients and health systems alike
The impact of improved glycaemic control with GLP-1 receptor agonist therapy on diabetic retinopathy
US$ 27.41
US$ 28.99
US$ 23.53
US$ 26.68
US$ 26.13
US$ 29.37
US$ 20.57
US$ 29.87
US$ 22.49
US$ 27.53
US$ 28.93
